Prostate Brachytherapy Sources Vary By $5,570, Violate 2X Rule – CAB Data
This article was originally published in The Gray Sheet
Executive Summary
Brachytherapy seeds for prostate cancer should be reimbursed by Medicare on a per-seed basis under the hospital outpatient prospective payment system, the Coalition for the Advancement of Brachytherapy (CAB) contends in Sept. 24 comments to CMS
You may also be interested in...
Brachytherapy Bill Could Be Included In Larger Medicare Package – Staffers
Theragenics is seeking a Senate sponsor for legislation that would oblige CMS to establish separate reimbursement for the number, isotope and radioactive intensity of sources used in brachytherapy under the hospital outpatient prospective payment system
Brachytherapy Bill Could Be Included In Larger Medicare Package – Staffers
Theragenics is seeking a Senate sponsor for legislation that would oblige CMS to establish separate reimbursement for the number, isotope and radioactive intensity of sources used in brachytherapy under the hospital outpatient prospective payment system
OPPS Rule Establishes Separate Palladium, Iodine G Codes For Brachytherapy
The Centers for Medicare & Medicaid Services will establish two new G codes to track prostate brachytherapy procedures, under the 2003 hospital outpatient prospective payment system final rule